Vas Narasimhan joins the power circle at Davos; Armo Bio, resTORbio raises $128M and $85M in IPO
→ With just a few more days before he officially becomes Novartis’ new CEO, Vas Narasimhan is joining the world’s power circle. Case in point: Narasimhan joined a group of big-time European CEOs who sat down with President Donald Trump for dinner at Davos.
→ Two IPOs pitched at a year-end blitz have materialized. Focusing on elderly respiratory tract infections, resTORbio has raised $85 million by offering 5.7 million shares at $15. The Cambridge, MA biotech plans to list as $TORC, a tribute to the mTORC1 inhibitors its founders believe have potential to treat a variety of aging-related ailments. Then there’s I/O player Armo Biosciences, which went above its original $86 million for 6.7 million shares plan and bagged $128 million instead with an offering of 7.5 million shares at $17. It will go on Nasdaq as $ARMO.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.